Difference between revisions of "Pertuzumab and Trastuzumab hyaluronidase (Phesgo)"
Jump to navigation
Jump to search
(Created page with "==General information== A combination of pertuzumab and trastuzumab, to be given by subcutaneous injection ==History of changes in FDA indication== *6/29/2020: Initial FDA ap...") |
m |
||
| Line 3: | Line 3: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2020-06-29: Initial FDA approval |
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | *12 | + | *2020-12-21: Initial authorization |
==Also known as== | ==Also known as== | ||
*'''Generic name:''' pertuzumab/trastuzumab/hyaluronidase-zzxf | *'''Generic name:''' pertuzumab/trastuzumab/hyaluronidase-zzxf | ||
Revision as of 23:47, 4 May 2023
General information
A combination of pertuzumab and trastuzumab, to be given by subcutaneous injection
History of changes in FDA indication
- 2020-06-29: Initial FDA approval
History of changes in EMA indication
- 2020-12-21: Initial authorization
Also known as
- Generic name: pertuzumab/trastuzumab/hyaluronidase-zzxf
- Brand name: Phesgo